Home » Topics » Regulatory » EMA

EMA
RSS

European orphan drug status recommended for QLT-091001 in LCA and RP

Feb. 11, 2011

Johnson & Johnson reports highlights fourth quarter 2010

Feb. 9, 2011

EMA grants orphan drug status to GT-038 in retinitis pigmentosa

Feb. 9, 2011

FluEnz approved in E.U. for prevention of seasonal flu in children

Feb. 7, 2011

EMA approves sublingual sildenafil formulation X-Excite for erectile dysfunction

Feb. 3, 2011

EMA confirms eligibility of Omeros' OMS-103HP for centralized marketing application

Feb. 2, 2011

Onyx initiates rolling NDA for carfilzomib in multiple myeloma

Feb. 1, 2011

CHMP recommends approval of BF-200 ALA for actinic keratosis

Feb. 1, 2011

Regadenoson approved in E.U. as an aid to diagnose CAD

Jan. 28, 2011

Clinical development of Pluristem Therapeutics' PLX-PAD advances

Jan. 28, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...